author-photo

Brian Higgins

Memorial Sloan Kettering Cancer Center

28

Papers

3277

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Abstract A082: A phase I study of the MDM2 antagonist RO6839921, a pegylated intravenous prodrug of idasanutlin, in patients with AML

2018 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

2012 Cancer Research
Show All
- Source
- Cite
- Save
Citations (139)
Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: Implications for therapy

2010 Cell Cycle
Show All
- Source
- Cite
- Save
Citations (26)
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

2010 Cancer Research
Show All
- Source
- Cite
- Save
Citations (342)
Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models

2010 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (27)
Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts

2009 Anticancer Research
Show All
- Source
- Cite
- Save
Citations (15)
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

2009 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (34)
Abstract #4420: PLX4032, a selective B-RafV600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models

2009 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model

2007 Anticancer Research
Show All
- Source
- Cite
- Save
Citations (21)
Traitement avec de l'irinotecan (cpt-11) et un inhibiteur egfr

2005
Show All
- Source
- Cite
- Save
Citations (0)